Medscape

Shorter but More Intense RT: A Better Option for Head and Neck Cancer?

A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in ...
Business Wire

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S.
ascopubs.org

Pembrolizumab in combination with chemotherapy as conversion therapy for esophageal squamous cell carcinoma with cervical lymph node metastasis: A single-center, prospective ...

Three-year and five-year outcomes of a phase II study of perioperative CapeOx therapy for advanced gastric cancer with extensive lymph node metastasis (OGSG1701). This is an ASCO Meeting Abstract from ...
CURE

How Recent Lung Cancer FDA Approvals are Shaping Treatment for Patients

Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program ...
Cure Today

Understanding Squamous Cell Lung Cancer and Common Treatment Paths

Squamous cell carcinoma treatment varies by stage, involving surgery, radiation, and systemic therapies based on cancer progression and patient health. Stage 1 focuses on tumor removal, Stage 2 ...
PharmiWeb

BeOne’s Tislelizumab Now Available in Ireland, Offering a New First Line Immunotherapy Option for Advanced Oesophageal Cancer

London, UK. 10 March 2026. BeOne Medicines (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today ...